Crizotinib for c-MET-amplified advanced NSCLC: a single-center experience.
Seher Yildiz TacarMesut YilmazBuge OzDeniz TuralPublished in: Tumori (2021)
Crizotinib is an effective treatment option other than cytotoxic chemotherapy in the limited number of patients with MET amplification in the stage 4 lung adenocarcinoma subgroup. It is important to investigate this amplification, which can be detected especially in smoking patients in the appropriate patient group, and to use appropriate tyrosine kinase inhibitors in treatment.